HONG KONG – Carsgen, a Chinese developer of cancer therapies, announced its completion of an undisclosed series A financing led by China-based health care private equity fund BVCF Management Ltd.

HONG KONG – 3SBio Inc., based in China's northeast city, Shenyang, entered a licensing agreement with Korean biotech company Pharmabcine Inc. to develop, manufacture and market the anti-vascular endothelial growth factor receptor 2 (VEGFR2) and kinase insert domain receptor antibody, tanibirumab. The deal could benefit up to 1 million cancer patients in China each year.

HONG KONG – A Chinese state-owned drug developer and distributor plans to raise as much as $700 million through a new share placement.

HONG KONG – 3SBio Inc., based in China's northeast city, Shenyang, entered into a licensing agreement with Korean biotech company Pharmabcine Inc. to develop, manufacture and market the anti-vascular endothelial growth factor receptor 2 (VEGFR2) and kinase insert domain receptor antibody, tanibirumab. The deal could benefit up to 1 million cancer patients in China each year.

HONG KONG – A Chinese vaccine and blood product maker is taking steps into the biosimilar market with four monoclonal antibody (MAb) biosimilar drugs.

HONG KONG – An immune-oncology drug developer in Beijing has successfully completed a first-round financing of more than ¥450 million (US$75 million).

HONG KONG – A Chinese vaccine and blood product maker is taking steps into the biosimilar market with four monoclonal antibody (MAbs) biosimilar drugs.

HONG KONG – China's proposed biosimilar guidelines could open the door for more competition among domestic and foreign producers even though some issues remain unclear, such as the development of more complex next-generation products and how regulators will deal with naming issues.